Results 101 to 110 of about 14,917 (240)
International Journal of Cancer, Volume 158, Issue 7, Page 1821-1835, 1 April 2026.What's new? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman +7 more
wiley +1 more source
Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.This systematic review synthesizes evidence from published studies, GWAS and grey literature (patents) to show that CAMK1D is implicated in diabetes, obesity, insulin resistance and altered feeding behaviours, with diagnostic potential and mechanistic relevance through regulatory binding and tissue‐specific effects.
Livio Tarchi +13 more
wiley +1 more source
Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.SpliCOOL‐seq achieves high‐throughput single‐cell co‐profiling of DNA methylation and chromatin accessibility. DNMT inhibitors caused cancer cell demethylation with divergent patterns. SpliCOOL‐seq enables the discovery of genes related to LUAD tumorigenesis. Ageing and LUAD tumorigenesis may share similar epigenetic alterations.
Qingmei Shen +6 more
wiley +1 more source
Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley +1 more source
Mediterranean Journal of Hematology and Infectious Diseases, 2012 Hypomethylating drugs are useful and approved in the management of myelodysplastic syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). However, phase 2 and 3 studies that assessed these agents in MDS, have included only a small number of CMML ...
Elena Elli +4 more
doaj +1 more source
DNTTIP1 drives leukaemogenesis through MiDAC‐mediated epigenetic silencing of BMF
Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.DNTTIP1 cooperates with SP1 to recruit HDAC1/2, leading to BMF silencing and reduced competitive binding of BMF to BCL2.This suppresses autophagy and apoptosis, promoting leukaemic cell survival. Targeting the DNTTIP1‐HDAC1/2‐BMF axis reactivates BMF and induces anti‐leukaemic effects.
Ruolin Xiu +12 more
wiley +1 more source
Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.(1) Core Process: Persistent antigen, from TDLNs to TME, drives Tpex → Tex‐int → Tex‐term differentiation. (2) Multiomics Regulation: This fate transition is orchestrated by a co‐ordinated, multi‐layered molecular network. (3) Functional Outcome: Dysregulated signalling and surging co‐inhibitory receptors lock in proliferative arrest and functional ...
Tong Zhu +5 more
wiley +1 more source
Myelodysplastic syndromes: therapeutic problems and decisions (review)
Онкогематология, 2014 Myelodysplastic syndromes (MDS) are a group of heterogeneous clonal disorders of myeloid hematopoietic stem cells characterized by an ineffective hematopoiesis associated with cytopenias, morphologic dysplasia and a progression to acute myeloid leukemia.
S. V. Semochkin +2 more
doaj +1 more source
HemaSphere, Volume 10, Issue 2, February 2026.Abstract Flow cytometry‐based measurable residual disease (MRD) testing is routinely used in acute myeloid leukemia (AML), but methodologies need refinement to optimize assay characteristics. Here, we examined 1215 adults with AML or myelodysplastic syndrome/AML allografted in morphologic remission to study how the type(s) of leukemic blasts and degree/
Calvin M. Le +8 more
wiley +1 more source